Today we are announcing Topos-2, our next-generation model for generating the full range of shapes a protein can take, across the order-disorder spectrum.
We are also previewing Topos-Bind: to our knowledge, the first generative model to capture the range of shapes for disordered proteins bound to small molecules.
Read the technical blog post here: toposbio.ai/topos-2-topos-bi…
(1/7)
Public databases do not provide disordered protein-ligand training data at scale, so we built Topos-DB: 100,000+ disordered protein-ligand systems simulated with all-atom MD.
To our knowledge, this is the largest all-atom protein MD dataset by distinct system count, roughly 3x the next largest.
(6/7)
The therapeutic opportunity lies in understanding, and ultimately controlling, the full distribution of conformations a protein can adopt.
If your program is limited by protein dynamics, we want to work with you: [email protected]
(7/7)
ToposBio retweeted
At Gladstone, collaboration fuels discovery. Our partnership with @ToposBio brings together AI-powered protein modeling and deep expertise in neurodegenerative disease to explore new therapeutic options for conditions like Parkinson’s and Alzheimer’s.
bit.ly/4sAewjD
Announcing Topos-1, an all-atom generative model that sets a new benchmark for predicting structural ensembles of intrinsically disordered proteins. Topos-1 outperforms existing models by a large margin, with implications for designing drugs for challenging targets ranging from cancer to neurodegenerative disease.
Read the full technical report on our website: toposbio.ai/tech-report
Powered by @Modal compute; shout out to @charles_irl
Excited to contribute to #DrugDesign #AI #Biology
Topos-1 is only the beginning: we’re rapidly expanding its capabilities and the favorable scaling results so far indicate a steep improvement curve. To learn more about the model and its evals, check out our technical report: toposbio.ai/tech-report





